Step 1 Flashcards
Which vasculitis is associated w/ HBV?
Polyarteritis Nodosa
vasculitis - string of pearls
Polyarteritis nodosa
which small vessel vasculitis have granulomas?
Granulomatosis with polyangiits (wegner)
Churg Strauss
Which small vessel vasculitis show lesions of different stages of healing
Wegners
which small vessel vasculitis is assocated with eosinophilia
Churg Strauss
differences between wegners and microscopic polyangitis
wegers: granulomas, different stages of healing, involving oral mucosa, c-ANCA (P3-ANCA)
microscopic: no granulomas, no nasopharyngeal, same stages, p-ANCA (MPO-ANCA)
which vasculitis is associated with migratory pulmonary infiltrate
Churg Strauss
Cyclosporin action
binds to cyclophilin to calcineurin (no dephosphorylation of NFAT) ability to transcribe IL-2
Tacrolimus action
blocks FK506 to inhibit calcineurin (no dephosphorylation of NFAT) to prevent IL-2 trascription
Cycolosporin vs. Tacrolimus ADRs
both nephrotoxic
Cyco: HTN, hyperlipid, hirsutism, gingival hyperplasia
tacrolimus: diabetes (no hirsutism or gingival)
Sirolimus
also rapamycin
binds to FKBP to inhibit mTOR to decrease T and B cell response to IL2
Synergisitc of cyclosporin
ADRs Sirolimus
pancytopenia, insulin resistance, NO nephrotoxicity
Daclizumab
IL2 Rect Ab
Basilizimab
IL2 Rec Ab
Azathioprine
Block PRPP amidotransferase to decrease purine NTs
6-mercaptopurine
blocks PRPP amidotransferase to decrease NTs
Mycophenolate
inhibits IMP dehydrogenase to decrease PUrine NT synthesis
Mycophenolate ADRs
GI upset, pancytopenia, HTN, hyperglycemia, CMV infection
Leflunomide
inhibits dihydroorate dehydrogenase to decrease pyrimidine NTs
Alemtuzumab
Anti CD52 (mature lymphocytes) for CLL
Bevacizumab
Anti VEGF
Use colorectal, RCC, WMD
Cetuximab
anti EGFR – colorectal CA
Rituximab
anti CD20 - B cell non-hodgkins, CLL, RA, ITP
Adalimumab
anti TNF alpha - IBD, RA, ankylosing spondylitis, psoriasis (increased susceptibility to TB)
Certolizumab
anti TNF alpha - IBD, RA, ankylosing spondylitis, psoriasis (increased susceptibility to TB)
Ifliximab
anti TNF alpha - IBD, RA, ankylosing spondylitis, psoriasis (increased susceptibility to TB)
Eculizumab
anti C5 (paroxysmal nocturnal hemoglobinuria)
Natalizumab
anti alpha4 integrin (decrease WBC adhesion) - MS, crohns - increased risk of PML with JC virus
Abciximab
anti iib/iiia - use for percutaneous coronary intervention
denosumab
anti RANKL
Omalizumab
anti IgE - prevents IgE from binding to FC
Palivizumab
anti RSV Fusion protein
Ranibizumab
Anti VEGF - wet macular degeneration
Ustekinumab
anti IL12 and IL23 - for NK and T activation - psoriasis
Imatinib
BCR-ABL and cKIT inihbitor
ADR: fluid retention
Erlotinib
tyrosine kinase inhibitor of EGFR
ADR: puplo-pustular rash
Afatinib
tyrosine kinase inhibitor of EGFR
Gefitinib
tyrosine kinase inhibitor of EGFR
Sorafenib
Tyrosine Kinase inhibitor of VEGF
ADRs: Hyperkeratosis and rash, increased hemorrhage
Sunitinib
Tyrosine Kinase inhibitor of VEGF
ADRs: Hyperkeratosis and rash, increased hemorrhage
Vemurafenib
BRAF kinase inhibitor (not tyrosine) of V600E used for metastatic melanoma
Theophylline
inhibits phosphodiesterase to decrease cAMP hydrolysis and increase cAMP –> bronchodilation and blocks Adeoosine receptor
rarely used in asthma due to risk of seizure and arrythmia
Type1 hypercholesterolemia
hyperchylomicronemia - defect LPL or C11
milky white blood wth high chylomicrons and TG (risk of pancreatitis, hepatosplenomegaly, xanthomas)
Type 2A hypercholesterolemia
defect in LDL receptor - increased risk of CAD, xanthomas, corneal arcus
Type 3 hypercholesterolemia
defect in ApoE –> increased IDL
Type 4 hyperchoelsterolemia
defect to cause increase VLDL with risk of pancreatitis
Abetaproteinemia
decrease in B48 and B100 to decrase chylomicrons –> accumulation in RBCs to crease acanthocytic RBCs, diarrhea, failure to thrive
which misregulated lipid metabolism increase risk of CVD
Type 2 - decreased LDL receptors
which misregulated lipid metabolism increase risk of pancreatitis
defect in LPL, C11 or increaed VLDL
VPL
thalamus - spinothalamic, dorsal column, medial leminisus
sensory body
VPM
thalamus sensory face
LGN
Input from CN II to calcarine sulcus - visual
MGN
input from superior olive and inferior colliculus to auditory cortex- sound
Anterior nucleus - thalamus
learning and memory
Pulvinar nucleus
integraes visual, aud, somatosensory
H line in muscle
Thick mysoin
I line in muscle
Thin actin
M line - muscle
middle of H line (myosin)
A- muscle
Thick myosin with actin overlap - doesn’t change
Oligomycin
inhibits ATP synthase
what inhibits cytochrome c
CO and cyanide
anamycinA
inhbit compelx 3 of ETC
Amobarbitol
inhbiits complex 1 of ETC
rotanone
inhibits complex 1 of ETC
what cause H+ leak
2,4 dinotrophenol, aspirin, thermogenin
H+ leakage - proton gradient and O2 consumption
decreases proton gradient and increase O2 consumption
what decreases H+ gradient and decrease O2 consumption in ETCs
inhibition of all complex
what increases H+ gradient and decrease O2 consumption
Oligomycin - ATP synthase
Glucokinase vs. Hexokinase
Glucokinase - low affinity (high Km) but high Vmax
Hexokinase - high affinity (low Km) but low Vmax
Cori
defect in alpha 1-6 dlugosiades - like Von Girks but without lactic acid or severe hypoglycemia
Andersons
branching enzyme defect
Hers
Defect in hepatic glycogen phosphorylase
Acetyl Co-A Carboxylase
FA synthesis - rate limiting
what is the rate limiting step in fatty acid synthesis
Acteyl Co-A Carboxylase
what shuttle is involved in FA synthesis
Citrate
RL step in beta ox
CAT1
Tryptophan makes
Niacin, NAD and NADP, serotonin, Melatonin